Sheng Hailong, Luo Yongyi, Zhong Liting, Wang Zhiyi, Sun Zhichao, Gao Xinna, He Xinrong, Zhu Zhenru, Wu Dehua, Sun Jingyuan, Cao Chuanhui
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Int J Radiat Oncol Biol Phys. 2025 Feb 1;121(2):534-546. doi: 10.1016/j.ijrobp.2024.09.024. Epub 2024 Sep 17.
Metastasis is one of the most important factors contributing to poor prognosis in hepatocellular carcinoma. Radiation therapy (RT), along with its induced abscopal effect, is a promising treatment for metastatic patients. However, the incidence of abscopal effect in clinical practice is rare, even when RT is combined with immune checkpoint inhibitors (ICIs). In this study, we aim to investigate the role of antiangiogenic treatment on the abscopal effect induced by RT + ICIs.
Bilateral subcutaneous and orthotopic Hepa1-6 and Hep53.4 models were established and treated with different combination treatments. We evaluated changes in the immune microenvironment and vascular normalization by flow cytometry, T cell receptor sequencing, chemotactic gene array, enzyme linked immunosorbent assays, and immunofluorescence.
Our studies showed that antiangiogenic treatment with RT + ICIs increased the antitumor response of the unirradiated lesions. Mechanistically, the blockade of vascular endothelial receptor 2 (anti-VEGFR2) increased the activation and maturation of dendritic cells and promoted the production of CD8 T cells in irradiated tumors. These CD8 T cells were attracted by anti-VEGFR2-induced CCL5 secretion from M1 macrophages in unirradiated tumors. Besides that, anti-VEGFR2 enhanced the function of CD8 T cells by reducing myeloid-derived suppressor cells and regulatory T cells.
This study demonstrated that the combination of antiangiogenic treatment with RT and ICIs enhanced the abscopal effects. The application of triple therapy and its induced abscopal effect may offer a novel therapeutic approach for hepatocellular carcinoma, particularly for cases with multiple metastatic lesions.
转移是导致肝细胞癌预后不良的最重要因素之一。放射治疗(RT)及其诱导的远隔效应是转移性患者一种有前景的治疗方法。然而,即使RT与免疫检查点抑制剂(ICIs)联合使用,远隔效应在临床实践中的发生率也很低。在本研究中,我们旨在探讨抗血管生成治疗对RT + ICIs诱导的远隔效应的作用。
建立双侧皮下和原位Hepa1-6及Hep53.4模型,并采用不同的联合治疗方法进行处理。我们通过流式细胞术、T细胞受体测序、趋化基因阵列、酶联免疫吸附测定和免疫荧光评估免疫微环境和血管正常化的变化。
我们的研究表明,RT + ICIs联合抗血管生成治疗可增强未照射病灶的抗肿瘤反应。机制上,血管内皮受体2阻断(抗VEGFR2)可增加树突状细胞的活化和成熟,并促进照射肿瘤中CD8 T细胞的产生。这些CD8 T细胞被未照射肿瘤中抗VEGFR2诱导的M1巨噬细胞分泌的CCL5吸引。除此之外,抗VEGFR2通过减少髓源性抑制细胞和调节性T细胞来增强CD8 T细胞的功能。
本研究表明,抗血管生成治疗与RT和ICIs联合可增强远隔效应。三联疗法的应用及其诱导的远隔效应可能为肝细胞癌,特别是多转移病灶的病例提供一种新的治疗方法。